CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop the next generation of targeted small molecule drug candidates for cancer treatment, today announced that the Company has selected an orally available, synthetic small molecule inhibitor of heat shock protein 90 (Hsp90) as a development candidate from its targeted cancer drug development platform. In addition to demonstrating potent efficacy across a broad range of cancers in preclinical cancer models, CUDC-305 exhibits promising pharmacological features, particularly its high oral bioavailability, high tumor penetration and extended tumor retention.
